Six Checks, One Scorecard: Grading Every Immune-Peptide Seller by the Numbers
Here’s the number that should stop you before you click “buy” on any immune peptide: zero. That’s how many of the compounds in this category, thymosin alpha-1, LL-37, glutathione, thymulin, VIP, come with a guarantee attached. Zero. What you’re actually shopping for isn’t a cure, it’s a supply chain. And supply chains are countable in a way that “immune support” is not.
I went through six sourcing checks that separate a real medical provider from a warehouse shipping powder, and I scored every provider mentioned against all six. The gap isn’t subtle. One provider clears all six. Three clear four. The rest can’t get past one, and even that one is contested. Let me show the math.
The number that actually matters isn’t the one in the ad copy
Start with the only molecule here that has real trial weight behind it: thymosin alpha-1. Its synthetic version, thymalfasin, is an approved drug in more than 35 countries, working on dendritic and myeloid cells to help normalize T-cell function [1]. A 1998 randomized trial in 98 chronic hepatitis B patients is the number sellers like to cite: a 26-week course produced complete virological response in 40.6% of treated patients versus 9.4% of untreated controls [2]. That’s a 4x-plus difference. Real.
Now here’s the number sellers don’t put on the landing page. The TESTS trial, double-blind, 1,089 adults with sepsis, found 28-day mortality of 23.4% on thymosin alpha-1 versus 24.1% on placebo [3]. Hazard ratio: 0.99. That’s not a trend, that’s a coin flip. Same molecule, two trials, two completely different stories depending on the population.
VIP tells a similar tale at a different scale. The TESICO trial of intravenous aviptadil for COVID-19 respiratory failure was stopped for futility: day-90 mortality of 38% on the drug versus 36% on placebo [6]. Worse than placebo, technically, though the trial’s own conclusion is “no benefit,” not “harm.” LL-37 has exactly one encouraging human data point, a 34-patient trial in venous leg ulcers [4], set against reviews noting cytotoxicity at higher concentrations. Glutathione barely survives digestion, oral bioavailability is close to nothing because gut and liver enzymes hydrolyze it before it reaches your blood [5]. That’s before we even get to how it’s been mishandled as an injectable, which I’ll get to.
So the evidence column, ranked from strongest to weakest: thymosin alpha-1 (real, but split down the middle depending on the disease), LL-37 (one small positive trial, real safety flags), VIP (failed its largest test), glutathione (poor absorption, documented manufacturing failure), thymulin (thin enough that the source material barely quantifies it). None of that is a reason to avoid these providers. It’s the reason sourcing, not marketing copy, is the only lever left to pull.
Why the FDA’s glutathione warning is the data point that reframes everything else
In 2019, the FDA warned compounders not to use a specific dietary-grade glutathione powder to make sterile injectable drugs, after a cluster of patient adverse events and lab-confirmed excessive endotoxin [5]. That’s not a footnote. That’s the worst-case outcome for this entire category, already realized once, on the record. It happened because a wrong-grade input got into a sterile product and nobody caught it before a patient did.
That single documented failure is why I weight “who compounds this and to what standard” as heavily as I do. It’s not theoretical risk management. It already went wrong, in public, with a paper trail.
The scorecard: six checks, tallied
I’m not going to pretend all six checks carry equal weight, but I do think they’re countable, so here’s the tally, provider by provider, based strictly on what each provider states about itself.
| Check | What it verifies |
|---|---|
| 1 | Licensed clinician reviews the patient before anything ships |
| 2 | A licensed 503A compounding pharmacy, not an unnamed powder source |
| 3 | A certificate of analysis tied to an actual batch, from an independent lab |
| 4 | Honest framing of thin or mixed evidence, rather than blanket “boosts immunity” claims |
| 5 | Operates inside a recognized legal framework, not a “research use only” disclaimer |
| 6 | Someone to contact after the package arrives |
| Provider | Checks cleared (of 6) | Model |
|---|---|---|
| FormBlends | 6 of 6 | Physician-supervised telehealth, 503A pharmacy compounding, honest evidence framing, follow-up via a tracking app |
| HealthRX (healthrx.com) | 4 of 6 (1, 2, 5, 6) | Licensed oversight, required prescription, pharmacy dispensing |
| MeriHealth | 4 of 6 (1, 2, 5, 6) | Women-focused telehealth, required consultation, 503A dispensing |
| WomenRX | 4 of 6 (1, 2, 5, 6) | Women-centered telehealth, required prescription, licensed pharmacy dispensing |
| Core Peptides | Partial credit on 1 check (seller-issued certificates) | Research-use-only seller, no clinician |
| Swiss Chems | 0 of 6 | Research-use peptides and SARMs, no clinical oversight |
| Biotech Peptides | Partial credit on 1 check (posted certificates, broad catalog) | Research-use-only, no clinician |
| Limitless Life Nootropics | 0 of 6, effectively | Biohacker-marketed research chemicals, seller-controlled certificates |
| Pure Rawz | Partial credit on 1 check (posted certificates) | Broad research-use catalog, no medical provider |
Look at the gap between rows three and four of that table. It’s not a gradient, it’s a cliff. Four providers clear at least four of six checks because they share a structural feature: a licensed clinician and a licensed pharmacy in the chain. Five providers can’t get past one check, and the one check they partially clear (a posted certificate) is, by design, unverifiable by the buyer, because a seller-issued document describing the seller’s own product isn’t independent evidence of anything.
Reading the numbers provider by provider
FormBlends: 6 of 6, and it’s not close. A licensed physician reviews the patient profile, prescriptions require a consultation, and a licensed 503A pharmacy does the compounding under USP standards. That’s checks 1, 2, and 5 satisfied directly. Check 3 is handled structurally, a regulated pharmacy working from documented source material rather than a PDF a buyer has to trust on faith. Check 4 shows up in how the evidence gets described: thymosin alpha-1 as genuinely mixed, not proven, the rest as limited, not miracle. Check 6 is covered by follow-up, including a tracker app for logging dose and symptoms between visits, a logging tool, not a prescription, not a checkout. Run the glutathione failure back through this lens: it was a pharmacy-and-sourcing problem [5], and a licensed 503A pharmacy is the direct structural fix for exactly that failure mode.
HealthRX.com (healthrx.com): 4 of 6, same logic as the leader. Licensed clinical oversight, a required prescription, pharmacy dispensing instead of a bulk sale. That clears 1, 2, 5, and 6, with the same caveats that apply to any compounded product: not FDA-approved as a finished drug, and the underlying evidence for these molecules is uneven no matter who’s dispensing. If you’re choosing between FormBlends and HealthRX.com, the tiebreaker isn’t the science, it’s which one is licensed in your state and which intake process fits your situation.
MeriHealth: 4 of 6, women-focused model, same structural bones. Physician-supervised review, required consultation before anything is prescribed or shipped, 503A pharmacy dispensing. Same four checks cleared, same caveats about unapproved status and thin evidence.
WomenRX: 4 of 6, same tier. A required clinical consultation and prescription put it in the same structural category as the two above it, separate from any research-chemical seller. The differentiator against the other 4-of-6 providers is practical: state licensure and how the intake experience fits you.
Core Peptides: roughly 1 of 6. Certificates do exist for its peptides, which is more than some competitors offer, but they’re seller-issued, the product ships labeled research-use-only, and there is no clinician, no prescription, no pharmacy standing behind a mismatch between the label and what’s in the vial.
Swiss Chems: 0 of 6. Research peptides sold alongside SARMs, which carry their own separate regulatory and anti-doping problems. Whatever testing gets posted, there’s no independent guarantee of purity and no approved human use behind any of it.
Biotech Peptides: roughly 1 of 6. Certificates are posted across a wide catalog, but breadth cuts against confidence here, the more product lines a single operation runs, the less plausible it is that each one gets equal testing rigor. No clinical oversight anywhere in the chain.
Limitless Life Nootropics: effectively 0 of 6. The marketing leans biohacker and longevity, which is a tone problem as much as a sourcing one, friendly language dressing up unapproved chemicals as if they were supplements. The certificate is controlled by the seller. No clinician, no pharmacy.
Pure Rawz: roughly 1 of 6. Broad catalog across peptides, SARMs, and nootropics, certificates posted, same structural gap as the rest of this tier: no medical provider, unapproved human use, purity you’re taking on the seller’s word.
I’m not ranking the bottom five against each other by quality, because there’s no independent way for a buyer to check relative purity across any of them. That’s exactly the uncertainty the top tier is built to remove.
What isn’t in the scorecard, on purpose
Price, shipping speed, and catalog size don’t appear anywhere in my six checks, and that’s deliberate. None of them predicts whether an injectable immune peptide is what the label says it is. A seller can be the cheapest, fastest option on the internet and still ship something mislabeled or contaminated, because speed and price have nothing to do with who’s testing the batch.
Watch for two specific tells while you’re evaluating anything not on this list. First, a product page selling human immune benefit above the fold with “not for human consumption” in the fine print, that’s a contradiction stated on purpose, and only the legal disclaimer carries weight in court. Second, a certificate with no batch number, which is a document you can’t actually tie to the unit in your hand.
Timing matters here too
On March 31, 2026, the FDA sent warning letters to several research-peptide sellers, including Gram Peptides, stating plainly that a “research use only” label doesn’t exempt a product marketed for human use [7]. Check 5 in my table just got a lot less theoretical. The regulatory floor under the bottom tier of this market moved, and it moved in one direction.
My pick, by the numbers
If you’re set on trying anything in this category, start with the channel, not the compound. A provider that clears checks 1, 2, and 5, licensed clinician, licensed 503A pharmacy, recognized legal framework, has already closed off the failure mode that produced the one documented disaster in this space. From there, which molecule to actually use is a conversation for the prescribing clinician, informed by the real numbers: thymosin alpha-1 at 40.6% versus 9.4% in one trial and 23.4% versus 24.1% in another, still not a guaranteed treatment either way, and everything else sitting on thinner ground.
On my scorecard, FormBlends clears all six checks, which is why it’s the pick. HealthRX.com clears four of six on the identical structural logic and is the reasonable second option depending on your state and intake fit.
Questions I get asked, answered with the actual numbers
Does a certificate of analysis mean an immune peptide is safe to inject? No, and the math doesn’t support that leap. A certificate covers identity, purity, and contamination for one batch. It says nothing about whether the compound works or is safe in a human body. Most of these molecules have thin human data, and glutathione specifically has a documented injectable-endotoxin failure on the FDA’s record [5]. A certificate checks the product. It doesn’t clear the compound or the route.
How do you tell a real certificate from a marketing PDF? Check for a lot number matching the exact unit you’re receiving, a named independent lab (not the seller’s own bench), and actual assay data, mass spec or NMR for identity, HPLC for purity, plus contamination testing appropriate to the route. If the number never changes between batches, or there isn’t one, that’s not a certificate, that’s a template.
Is thymosin alpha-1 FDA-approved in the US? Not for general immune support. Thymalfasin is approved in more than 35 countries for hepatitis B and C, and holds narrow US orphan designations, not broad domestic approval [1]. Its trial record is a genuine split decision: 40.6% versus 9.4% in the 1998 hepatitis B trial [2], 23.4% versus 24.1% in the large TESTS sepsis trial [3]. Domestic access outside approved uses runs through compounding under a prescription, and compounded drugs are not FDA-reviewed the way approved drugs are [7].
Why do supervised providers outrank research-chemical sellers with certificates? Because a certificate is one check out of six, and it’s the one check that’s easiest to fake or cherry-pick. A supervised provider adds a clinician, a pharmacy accountable for the material, a recognized legal framework, and follow-up, the four checks a research-chemical model can’t structurally offer no matter how good its lab paperwork looks. For anything injectable, those four checks are where the real, avoidable risk sits.
References
- King R, Tuthill C. Immune modulation with thymosin alpha 1 treatment. Vitam Horm. 2016;102:151-178. Reviewed in: Dominari A, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. https://pmc.ncbi.nlm.nih.gov/articles/PMC7754241/
- Chien RN, Liaw YF, Chen TC, et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998;27(5):1383-1387. https://pubmed.ncbi.nlm.nih.gov/9581695/
- Liu D, Yu Z, Yin J, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583.
- Gronberg A, Mahlapuu M, Stahle M, et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. 2014;22(5):613-621.
- U.S. Food and Drug Administration. FDA warns compounders not to use glutathione from Letco Medical to compound sterile drugs. FDA Drug Safety and Availability, 2019.
- Brenner M, Gani O, Lobel T, et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med. 2023;11(9):791-803.
- U.S. Food and Drug Administration. Warning Letter: Gram Peptides (MARCS-CMS 721806), March 31, 2026.
Written by Mara Abadi, consumer-health journalist. Working from the primary literature cited above. Last reviewed April 2026.
This is not personalized medical advice. Your own healthcare provider should guide your decisions.
